|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using c-MET, DPC4, and thymidylate synthase, we developed a multi-protein predictor that could be used to risk-stratify patients and guide decisions regarding the sequencing of locoregional and systemic therapies in pancreatic cancer.
|
29229329 |
2018 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
The TS-ZEB1 association was confirmed in clinical specimens from lung tumours and in a genetic mouse model of pancreatic cancer with ZEB1 deletion.
|
28337746 |
2017 |
|
Malignant neoplasm of pancreas
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we investigated the effect of three DNA polymorphisms within the thymidylate synthase gene and two within hypoxia inducible factor-1α on the prognosis of pancreatic cancer.
|
22825513 |
2012 |
|
Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These data warrant large-scale clinical studies to assess the role of polymorphisms in the TS gene on its protein expression and chemosensitivity to 5-FU in pancreatic cancer.
|
21362378 |
2011 |
|
Malignant neoplasm of pancreas
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.
|
20306339 |
2011 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer.
|
20944490 |
2010 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
CTD_human |
Among the lung and pancreatic cancers, 50-74% showed low TS/high DPD expression.
|
19020767 |
2008 |
|
Malignant neoplasm of pancreas
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We conducted a case-control study to assess the effect of alcohol on pancreatic cancer in conjunction with polymorphisms in one-carbon metabolism enzymes, methylenetetrahydrofolate reductase (MTHFR C677T), methionine synthase (MTR A2756G), methionine synthase reductase (MTRR A66G), and thymidylate synthase (TS) variable number of tandem repeat.
|
18843018 |
2008 |
|
Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Among the lung and pancreatic cancers, 50-74% showed low TS/high DPD expression.
|
19020767 |
2008 |
|
Malignant neoplasm of pancreas
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
An increased risk of pancreatic cancer was also associated with the TS 3Rc/3Rc genotype (OR, 2.19, 95% CI, 1.13-4.31; P = .022) compared with the TS 3Rg/3Rg genotype.
|
16234002 |
2005 |
|
Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Therefore, we explored the hypothesis that TS expression was associated with patient prognosis and the response to adjuvant therapy in pancreatic cancer.
|
14519641 |
2003 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dr Mayer concluded by presenting a series of hypothetical agenda items for the Fourth International Conference on Biology, Prevention, and Treatment of Gastrointestinal Malignancies to be held in the new millennium which he hoped would demonstrate the incorporation of biological agents into clinical trials, would document more concerted efforts to study the biology and improve the treatment for pancreatic cancer, and would begin to consider the use of 'risk-adapted' management strategies into clinical trials, based on such preclinical biological markers as intratumoral thymidylate synthase levels, apoptotic indices, allelic deletions, and the like.
|
10355571 |
1999 |